At Health Enterprise East we believe in improving healthcare through technology and innovation
The Challenge The team at Open Medical have developed a novel teledermoscopy tool aimed to enhance the triage of dermatology referrals, particularly for suspected skin cancer. This tool holds the promise to considerably shorten the journey from referral to the final diagnosis, optimising the utilisation of healthcare resources. The innovators asked HTE to use its expertise to […]
The client had a novel product for use in patients with irritable bowel syndrome (IBS) and wished to have its product listed on the NHS Drug Tariff. To support the application, a health economic evaluation was required to demonstrate the relative cost-effectiveness of the intervention.
The team at the Electrospinning Company have developed a novel synthetic material intended for use as a graft in ophthalmic surgery. The innovative material has the potential to improve surgical outcomes in addition to being more economical that the currently used graft options.
An innovator has developed a smart referral solution. The innovation is expected to enhance efficiencies in primary and secondary care by reducing inappropriate referrals, excessive secondary care appointments, repeat GP consultations, and the administrative burden associated with triaging and managing incorrect referrals.
The innovators had developed a digital dietary education program, targeting adults with a BMI greater than 25. The program is accessible through a website and also on a mobile app, it offers structured meal plans to the user.
The innovators at Aker Health Tech have developed an automated, self-propelled robotic colonoscopy device, capable of performing a complete colonoscopy for the lower gastrointestinal tract. This innovation is projected to significantly reduce the duration of the colonoscopy procedure and the required staffing resources.
Our client has developed an innovative tumour-grading technology that has the potential to revolutionize breast cancer treatment. This technology enables the stratification of patients based on their risk of cancer recurrence, aiming to reduce the amount of unnecessary chemotherapy treatments that are delivered.
Lucida Medical develops software based on artificial intelligence methods (machine learning and image processing) to enable radiologists to find cancer accurately, consistently, and quickly using MRI. Innovators at Lucida Medical developed Prostate Intelligence (PI™) to support the diagnosis of prostate cancer in patients.
InnoScot Health work in close partnership with NHS Scotland to support the development of innovative ideas to improve patient care. They identified the need for a value assessment tool to enable their team to evaluate early-stage innovations, identify viable opportunities and efficiently allocate resources to deliver value and improvement to the NHS.
Innovators from the Department of Clinical Neurosciences at the University of Cambridge had developed a machine learning algorithm to predict the speed of progression of Alzheimer’s disease. This decision support tool would enable physicians to better manage their patients by assigning them to the most appropriate treatment pathway.
ONX is a non-invasive molecular test developed by UK based Cambridge Oncometrix. The test will enable risk-stratification and improve true positive rates within the diagnostic pathway for those with suspected prostate cancer. ONX will be conducted prior to multi-parametric magnetic resonance imaging scanning, a relatively new prostate cancer screening method. As a result, ONX will alleviate the burden placed on access to mpMRI scans.